In response: The RNS System multicenter randomized double-blinded controlled trial of responsive cortical stimulation for adjunctive treatment of intractable partial epilepsy: Knowledge and insights gained

Abstract Background The 2019 coronavirus disease (COVID-19) pandemic continues to spread and affects large numbers of people with unprecedented impacts. To date, there is no consensus on a specific treatment. Experimental evidence has already been obtained for use of the standardized extract of Brazilian green propolis (EPP-AF) against viral targets, and clinical rationality has been demonstrated for testing this extract as an adjunct to treatment in patients affected by COVID-19. The BeeCovid2 study is once again assessing EPP-AF in hospitalized patients with coronavirus infection. Methods BeeCovid2 is a randomized, double-blinded, placebo-controlled clinical study being conducted in Brazil to provide further evidence on the effectiveness of standardized green propolis extract as an adjunctive treatment for adults hospitalized with COVID-19. Adults hospitalized with COVID-19 with respiratory symptoms for less than 14 days who are not on invasive oxygen therapy are eligible. Enrolled patients are randomized at a 1:1 ratio to receive placebo or standardized propolis extract (900 mg/day) for 10 days. The study treatments are administered in a double-blinded manner, and patients are followed for 28 days. The primary outcome is the length of hospital stay. Secondary outcomes include the need for mechanical ventilation, the rate of acute kidney injury, the need for renal replacement therapy, the requirement for vasoactive drugs, the use of an intra-aortic balloon pump (IABP), and the use of extracorporeal membrane oxygenation (ECMO). Discussion This trial is very useful and will provide more data on the effectiveness of using the standardized Brazilian green propolis extract as an adjunctive treatment in association with standard care in adults hospitalized with moderate to severe acute COVID-19. Trial registration: ClinicalTrials.gov NCT04800224. Registered on March 16, 2021.

Download Full-text

Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Two Opioid-minimizing Pain Management Regimens Following Transsphenoidal Surgery: An Interim Analysis

Journal of Neurological Surgery Part B Skull Base ◽

10.1055/s-0036-1579846 ◽

2016 ◽

Vol 77 (S 01) ◽

Author(s):

Andrew Little ◽

Deborah Shepherd ◽

Heidi Jahnke ◽

William White

Keyword(s):

Pain Management ◽

Interim Analysis ◽

Transsphenoidal Surgery ◽

Controlled Trial ◽

Double Blinded

Download Full-text

Prospective, Randomised, Double-Blinded, Placebo-Controlled Trial of Glyceryl Trinitrate Ointment in the Treatment of Early Symptomatic Haemorrhoids

Endoscopy ◽

10.1055/s-2004-834525 ◽

2004 ◽

Vol 36 (10) ◽

Author(s):

M Aslam ◽

S Humadi

Keyword(s):

Glyceryl Trinitrate ◽

Controlled Trial ◽

Double Blinded ◽

Glyceryl Trinitrate Ointment

Download Full-text

Crystalloid vs colloid for intraoperative resuscitation using a closed-loop system for unbiased treatment: a randomized double blinded controlled trial

10.26226/morressier.58f5b031d462b80296c9d5ae ◽

2017 ◽

Author(s):

Amélie Delaporte

Keyword(s):

Closed Loop ◽

Controlled Trial ◽

Loop System ◽

Closed Loop System ◽

Double Blinded

Download Full-text

A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolaminein Individuals With Bipolar Disorder

Case Medical Research ◽

10.31525/ct1-nct04211961 ◽

2019 ◽

Author(s):

Keyword(s):

Bipolar Disorder ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blinded

Download Full-text

Therapeutic Effects of Hab Shabyar on Open-Angle Glaucoma: A Double-Blinded, Randomized, Placebo-Controlled Trial

10.31661/gmj.v0i0.1218 ◽

2019 ◽

Vol 8 ◽

pp. 1218

Author(s):

Ebrahim Khalil BaniHabib ◽

Ali Mostafai ◽

Seyyed Mohammad Bagher Fazljou ◽

Ghadir Mohammdi

Keyword(s):

Placebo Group ◽

Intraocular Pressure ◽

Open Angle Glaucoma ◽

Controlled Trial ◽

Intervention Group ◽

Therapeutic Effects ◽

Open Angle ◽

The Mean ◽

The Right ◽

Double Blinded

Background: Open-angle glaucoma (OAG) is one of the leading causes of blindness worldwide. This study evaluates the therapeutic effects of hab shabyar in patients with open-angle glaucoma. Materials and Methods: In this clinical randomized controlled trial, 50 patients with OAG were randomized into two groups. The intervention group was received a drop of timolol plus 500 mg of hab shabyar every 12 hours. The placebo group was received a drop of timolol every 12 hours plus 500 mg of wheat germ as a placebo. The intraocular pressure in patients with OAG was measured in each group and compared at before the intervention (t1), one month (t2), and two months (t3) after the intervention. Results: The mean decrease in intraocular pressure for the right eye at three times in the intervention group was statistically significant, but the mean decrease in the placebo group was not significant. Similar results were obtained for the left eye at t1 when compared to t3. The patients in the intervention group expressed more satisfaction than the patients in the placebo group (P≤0.001). Conclusion: Our study demonstrated that consumption of timolol plus hab shabyar instead of consuming of timolol alone was probably more effective for reducing intraocular pressure in patients with OAG.[GMJ.2019;In press:e1218]

Download Full-text